首页> 美国卫生研究院文献>Gut >Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry
【2h】

Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry

机译:谁能在胰腺导管腺癌中生存?一项全国性的研究对芬兰癌症登记处的数据进行了重新评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Worldwide survival data for ductal adenocarcinoma of the pancreas are the lowest among the 60 most frequent types of organ cancers. Hence published data on long time survivors of this disease are controversial. We performed a nationwide study comprising all Finnish patients diagnosed with pancreatic cancer in the period 1990–1996 who survived for at least five years after diagnosis.>Methods: Data on patients registered as five year survivors of pancreatic cancer were obtained from the Finnish Cancer Registry and Statistics Finland. Slides or paraffin blocks were collected from patients recorded as having histologically proven pancreatic ductal adenocarcinoma (PDAC) and were re-evaluated in a double blind fashion by three pathologists with special expertise in pancreatic pathology.>Results: Between 1990 and 1996, the Finnish Cancer Registry recorded 4922 pancreatic cancer patients, 89 of whom survived for at least five years. Reviewing this series of patients revealed 45 (49%) non-PDACs and 18 cases without histological verification. In 26 patients recorded as having histologically proven PDAC, re-evaluation of histological specimens confirmed PDAC in only 10 patients.>Conclusions: This study indicates that (1) the prognosis of PDAC remains poor and (2) careful histopathological review of all patients with pancreatic cancer is mandatory if survival data are to be meaningful.
机译:>背景:胰腺的导管腺癌的全球生存数据在60种最常见的器官癌中是最低的。因此,有关该病长期幸存者的公开数据存在争议。我们进行了一项全国性研究,纳入了1990-1996年期间所有诊断为胰腺癌的芬兰患者,这些患者在诊断后至少存活了五年。>方法:从芬兰癌症登记和统计局获得。从经组织学证实为胰腺导管腺癌(PDAC)的患者中收集载玻片或石蜡块,然后由三位具有胰腺病理学专门知识的病理学家以双盲方式对其进行重新评估。>结果:和1996年,芬兰癌症登记处记录了4922位胰腺癌患者,其中89位存活了至少五年。回顾这一系列患者,发现45例(49%)非PDAC和18例未经组织学证实。在26例经组织学证实为PDAC的患者中,组织学标本的重新评估仅在10例患者中证实了PDAC。>结论:该研究表明,(1)PDAC的预后仍然很差,(2)谨慎如果要使生存数据有意义,必须对所有胰腺癌患者进行组织病理学检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号